The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Guidance for community oncologists treating patients with relapsed IDH1-mutated AML
Agnieszka Wierzbowska, MD, PhD, Medical University of Lodz, Lodz, Poland, provides guidance for treating patients with IDH1-mutated acute myeloid leukemia (AML) who have relapsed after initial therapy with IDH1 inhibitors. She notes that available data indicate these patients remain sensitive to venetoclax-based therapies and suggests using venetoclax in combination with azacitidine or with a hypomethylating agent. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
